Swiss drug company Roche has entered into a definite merger agreement to acquire Anadys Pharmaceuticals for $230 million.

The company said on Monday that it will buy Anadys, a developer of oral and small molecule therapeutics for the treatment of hepatitis C (HCV), for $3.70 a share in an all-cash transaction.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Setrobuvir (ANA598), Anadys’ most advanced drug candidate, is currently being evaluated by Anadys in a Phase II study in combination with Roche’s pegylated interferon (Pegasys) and ribavirin (Copegus).

Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development, said: "This acquisition augments our already strong HCV portfolio. Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."

Anadys is also developing ANA773, an oral, small-molecule inducer of innate immunity in Phase I trials that may prove useful for treating HCV and cancer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now